- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/605 - Glucagons
Détention brevets de la classe C07K 14/605
Brevets de cette classe: 1408
Historique des publications depuis 10 ans
|
131
|
97
|
113
|
90
|
134
|
138
|
136
|
165
|
126
|
41
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novo Nordisk A/S | 2324 |
109 |
| Hanmi Pharm. Co., Ltd. | 546 |
78 |
| Zealand Pharma A/S | 211 |
75 |
| Eli Lilly and Company | 3645 |
60 |
| Sanofi | 3836 |
47 |
| Indiana University Research and Technology Corporation | 808 |
21 |
| Merck Sharp & Dohme LLC | 3689 |
18 |
| Takeda Pharmaceutical Company Limited | 2961 |
17 |
| Intarcia Therapeutics, Inc. | 114 |
17 |
| MedImmune Limited | 627 |
17 |
| Hanmi Science Co., Ltd. | 145 |
16 |
| The Scripps Research Institute | 1364 |
14 |
| President and Fellows of Harvard College | 5792 |
13 |
| Hybio Pharmaceutical Co., Ltd. | 119 |
13 |
| Sun Pharmaceutical Industries Limited | 706 |
13 |
| Duke University | 2872 |
12 |
| Bachem Holding AG | 36 |
12 |
| Heptares Therapeutics Limited | 225 |
11 |
| Merck Sharp & Dohme Corp. | 2247 |
10 |
| Boehringer Ingelheim International GmbH | 4629 |
10 |
| Autres propriétaires | 825 |